Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288481 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
A Phase 1 study of Tuberculosis, sponsored by Global Alliance for TB Drug Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02288481: Completed Phase 1 study of Tuberculosis, sponsored by Global Alliance for TB Drug Development.
NCT02288481 is a Phase 1 study of Tuberculosis that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 48 participants, below the 933-participant average among 29 other Tuberculosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288481, a Phase 1 study of Tuberculosis, has completed, sponsored by Global Alliance for TB Drug Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TBA-354
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
What the finished NCT02288481 record still lists
NCT02288481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 933-participant average among 29 other Tuberculosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02288481 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT02288481 about?
NCT02288481 is a clinical study titled "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects". The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.
What is the current status of trial NCT02288481?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2015-01. Estimated completion is 2015-06.
What conditions does trial NCT02288481 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT02288481?
The interventions under investigation include: Placebo (OTHER), TBA-354 (DRUG).
Who is sponsoring clinical trial NCT02288481?
This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288481 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02288481's enrollment target sits among peer trials
48 23rd of 29 higher than 7 of 29 other Tuberculosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
COMPLETED · Phase 1
-
Phase I Trial of DAR-901
COMPLETED · Phase 1
-
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
COMPLETED · Phase 1
-
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
COMPLETED · Phase 1
-
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia